ARROWHEAD PHARMACEUTICALS, INC. Research and Development Expense
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Research and Development Expense of $198.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- ARROWHEAD PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-06-30 was $198.22M, a 22.08% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-03-31 was $173.25M, a 30.17% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-12-31 was $177.20M, a 29.34% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-09-30 was $174.69M.
- ARROWHEAD PHARMACEUTICALS, INC. research and development expense for fiscal 2025 was $607.16M, a 20.02% increase from fiscal 2024.
- ARROWHEAD PHARMACEUTICALS, INC. research and development expense for fiscal 2024 was $505.87M, a 43.23% increase from fiscal 2023.
- ARROWHEAD PHARMACEUTICALS, INC. research and development expense for fiscal 2023 was $353.19M.
- ARROWHEAD PHARMACEUTICALS, INC. research and development expense for fiscal 2015 was $47.27M, a 104.28% increase from fiscal 2014.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 98 month | Research and Development Expense 101 month | Research and Development Expense 104 month | Research and Development Expense 107 month | Research and Development Expense 110 month | Research and Development Expense 113 month | Research and Development Expense 116 month | Research and Development Expense 119 month | Research and Development Expense 122 month | Research and Development Expense 125 month | Research and Development Expense 128 month | Research and Development Expense 131 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $198.22M 10-Q · filed 2026-08-04 | $371.48M derived: sum of 2 quarters · filed 2026-08-04 | $548.68M 10-Q · filed 2026-08-04 | $723.37M derived: sum of 4 quarters · filed 2026-08-04 | |||||||||||||
| 2026-03-31 | $173.25M 10-Q · filed 2026-05-07 | $350.46M 10-Q · filed 2026-05-07 | $525.14M derived: sum of 3 quarters · filed 2026-05-07 | $687.51M derived: sum of 4 quarters · filed 2026-08-04 | |||||||||||||
| 2025-12-31 | $177.20M 10-Q · filed 2026-02-05 | $351.89M derived: sum of 2 quarters · filed 2026-02-05 | $514.26M derived: sum of 3 quarters · filed 2026-08-04 | $647.36M derived: sum of 4 quarters · filed 2026-08-04 | |||||||||||||
| 2025-09-30 | $174.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $337.06M derived: sum of 2 quarters · filed 2026-08-04 | $470.16M derived: sum of 3 quarters · filed 2026-08-04 | $607.16M 10-K · filed 2025-11-25 | |||||||||||||
| 2025-06-30 | $162.37M 10-Q · filed 2026-08-04 | $295.47M derived: sum of 2 quarters · filed 2026-08-04 | $432.47M 10-Q · filed 2026-08-04 | ||||||||||||||
| 2025-03-31 | $133.10M 10-Q · filed 2026-05-07 | $270.10M 10-Q · filed 2026-05-07 | |||||||||||||||
| 2024-12-31 | $137.00M 10-Q · filed 2026-02-05 | ||||||||||||||||
| 2024-09-30 | $505.87M 10-K · filed 2025-11-25 | ||||||||||||||||
| 2023-09-30 | $353.19M 10-K · filed 2025-11-25 | ||||||||||||||||
| 2015-09-30 | $10.39M derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-14 | $17.88M derived: sum of 2 quarters · filed 2015-12-14 | $29.52M derived: sum of 3 quarters · filed 2015-12-14 | $47.27M 10-K · filed 2015-12-14 | |||||||||||||
| 2015-06-30 | $7.49M 10-Q · filed 2015-08-04 | $19.13M derived: sum of 2 quarters · filed 2015-08-04 | $36.88M 10-Q · filed 2015-08-04 | $45.29M derived: sum of 4 quarters · filed 2015-12-14 | |||||||||||||
| 2015-03-31 | $11.64M 10-Q · filed 2015-05-11 | $29.39M 10-Q · filed 2015-05-11 | $37.80M derived: sum of 3 quarters · filed 2015-12-14 | $44.20M derived: sum of 4 quarters · filed 2015-12-14 | |||||||||||||
| 2014-12-31 | $17.74M 10-Q · filed 2015-02-09 | $26.16M derived: sum of 2 quarters · filed 2015-12-14 | $32.55M derived: sum of 3 quarters · filed 2015-12-14 | $37.77M derived: sum of 4 quarters · filed 2015-12-14 | |||||||||||||
| 2014-09-30 | $8.42M derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-14 | $14.81M derived: sum of 2 quarters · filed 2015-12-14 | $20.03M derived: sum of 3 quarters · filed 2015-12-14 | $23.14M 10-K · filed 2015-12-14 | |||||||||||||
| 2014-06-30 | $6.39M 10-Q · filed 2015-08-04 | $11.61M derived: sum of 2 quarters · filed 2015-08-04 | $14.72M 10-Q · filed 2015-08-04 | $17.99M derived: sum of 4 quarters · filed 2015-12-14 | |||||||||||||
| 2014-03-31 | $5.22M 10-Q · filed 2015-05-11 | $8.35M 10-Q · filed 2015-05-11 | $11.60M derived: sum of 3 quarters · filed 2015-12-14 | $13.35M derived: sum of 4 quarters · filed 2015-12-14 | $59.67M 10-Q · filed 2014-05-06 | ||||||||||||
| 2013-12-31 | $3.13M 10-Q · filed 2015-02-09 | $6.38M derived: sum of 2 quarters · filed 2015-12-14 | $8.14M derived: sum of 3 quarters · filed 2015-12-14 | $10.26M derived: sum of 4 quarters · filed 2015-12-14 | $54.46M 10-Q · filed 2014-02-04 | ||||||||||||
| 2013-09-30 | $3.25M derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-14 | $5.00M derived: sum of 2 quarters · filed 2015-12-14 | $7.13M derived: sum of 3 quarters · filed 2015-12-14 | $8.71M 10-K · filed 2015-12-14 | $51.32M 10-K · filed 2013-12-18 | ||||||||||||
| 2013-06-30 | $1.76M 10-Q · filed 2014-08-12 | $3.88M derived: sum of 2 quarters · filed 2014-08-12 | $5.46M 10-Q · filed 2014-08-12 | $7.50M derived: sum of 4 quarters · filed 2014-11-25 | $48.08M 10-Q · filed 2013-08-07 | ||||||||||||
| 2013-03-31 | $2.13M 10-Q · filed 2014-05-06 | $3.70M 10-Q · filed 2014-05-06 | $5.75M derived: sum of 3 quarters · filed 2014-11-25 | $6.97M derived: sum of 4 quarters · filed 2014-11-25 | $46.32M 10-Q · filed 2013-05-09 | ||||||||||||
| 2012-12-31 | $1.58M 10-Q · filed 2014-02-04 | $3.62M derived: sum of 2 quarters · filed 2014-11-25 | $4.84M derived: sum of 3 quarters · filed 2014-11-25 | $6.20M derived: sum of 4 quarters · filed 2014-11-25 | $44.20M 10-Q · filed 2013-02-13 | ||||||||||||
| 2012-09-30 | $2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2014-11-25 | $3.26M derived: sum of 2 quarters · filed 2014-11-25 | $4.62M derived: sum of 3 quarters · filed 2014-11-25 | $5.39M 10-K · filed 2014-11-25 | $42.62M 10-K · filed 2012-12-28 | ||||||||||||
| 2012-06-30 | $1.22M 10-Q · filed 2013-08-07 | $2.58M derived: sum of 2 quarters · filed 2013-08-07 | $3.35M 10-Q · filed 2013-08-07 | $3.86M derived: sum of 4 quarters · filed 2013-08-07 | $40.57M 10-Q · filed 2012-08-13 | ||||||||||||
| 2012-03-31 | $1.36M 10-Q · filed 2013-05-09 | $2.13M 10-Q · filed 2013-05-09 | $2.64M derived: sum of 3 quarters · filed 2013-05-09 | $3.00M derived: sum of 4 quarters · filed 2013-05-09 | $39.36M 10-Q · filed 2012-05-08 | ||||||||||||
| 2011-12-31 | $769.07K 10-Q · filed 2013-02-13 | $1.14M 10-Q · filed 2012-02-09 | $1.28M derived: sum of 2 quarters · filed 2013-02-13 | $1.64M derived: sum of 3 quarters · filed 2013-02-13 | $1.78M derived: sum of 4 quarters · filed 2013-02-13 | $41.57M 10-Q · filed 2012-02-09 | |||||||||||
| 2011-09-30 | $509.63K derived: 10-K 12 month − 10-Q 9 month · filed 2012-12-28 | $875.25K derived: sum of 2 quarters · filed 2012-12-28 | $1.02M derived: sum of 3 quarters · filed 2012-12-28 | $3.28M 10-K · filed 2012-12-28 | $40.43M 10-K · filed 2011-12-20 | ||||||||||||
| 2011-06-30 | $365.62K 10-Q · filed 2012-08-13 | $506.28K derived: sum of 2 quarters · filed 2012-08-13 | $2.77M 10-Q · filed 2012-08-13 | $2.93M derived: sum of 4 quarters · filed 2012-08-13 | $39.92M 10-Q · filed 2011-08-08 | ||||||||||||
| 2011-03-31 | $140.66K 10-Q · filed 2012-05-08 | $2.40M 10-Q · filed 2012-05-08 | $2.56M derived: sum of 3 quarters · filed 2012-05-08 | $2.68M derived: sum of 4 quarters · filed 2012-05-08 | |||||||||||||
| 2010-12-31 | $2.26M 10-Q · filed 2012-02-09 | $2.42M derived: sum of 2 quarters · filed 2012-02-09 | $2.54M derived: sum of 3 quarters · filed 2012-02-09 | ||||||||||||||
| 2010-09-30 | $157.05K derived: 10-K 12 month − 10-Q 9 month · filed 2011-12-20 | $280.39K derived: sum of 2 quarters · filed 2011-12-20 | $529.60K 10-K · filed 2011-12-20 | ||||||||||||||
| 2010-06-30 | $123.34K 10-Q · filed 2011-08-08 | $372.55K 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |